Table 1
Patient Demographics and Clinical Characteristics
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
|---|---|---|---|---|
| Age (years) | 54 | 61 | 53 | 33 |
| Gender | Male | Female | Female | Female |
| Disease duration (years) | 3 | 21 | 1 | 1 |
| Diagnosis | Cervical dystonia | Cervical dystonia | Cervical dystonia | Cervical dystonia |
| Pharmacotherapy | Botulinum toxin type A | Botulinum toxin type A | Botulinum toxin type A | Botulinum toxin type A |
| Description of cervical dystonia | “Right laterocollis with right shoulder elevation” | “Left dystonic neck, left torticollis, right laterocollis” | “Slight right laterocollis and slight anterocollis” | “Right torticollis, mild anterocollis and mild right laterocollis with right shoulder elevation” |
Figure 1
Patient 1, MEG Images Pre and Post Botulinum Toxin. Regions of the brain that are different pre (green) and post (red) medication in this subject who took botulinum toxin. Red areas indicate where more coherent activity was seen after treatment. Green areas had higher coherence prior to treatment.
Figure 2
Difference in Coherence between Patients and Controls, Pre and Post-Botulinum Toxin. (A) The biggest difference in coherence seen in the fronto-striatal, occipito-striatal, parieto-striatal, and temporo- striatal areas in controls compared with patients. (B) With botulinum toxin, there is an increase in coherence overall in the above-mentioned pathways in controls compared with patients. (C) Comparing cervical dystonia patients, coherence networks increased after medication, especially in the frontal–frontal, frontal–parietal, frontal–temporal, and cingulate–occipital pathways.
